カテゴリ： GlobalData, アメリカ, 企業調査

Alexion Pharmaceuticals Inc (ALXN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Alexion Pharmaceuticals Inc (ALXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10079
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：134
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Alexion Pharmaceuticals Inc (Alexion) focuses on developing and delivering life-changing drug therapies for patients with serious and ultra-rare disorders. The company develops biologic therapeutic products for the treatment of severe disease states, including genetic diseases, hematologic diseases, cancer, neurological and autoimmune disorders. The company’s marketed product portfolio includes Soliris (eculizumab) used for two indications paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (AHUS); Strensiq (asfotase alfa) for the treatment of hypophosphatasia (HPP)and Kanuma (sebelipase alfa) for the treatment of Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D). The company’s research and development activities focus on developing its lead product Soliris, for various other serious disease states. It also has other candidates in development targeting rare metabolic and inflammatory disorders. Alexion is headquartered in New Haven, Connecticut, the US.

Alexion Pharmaceuticals Inc (ALXN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Wilson Therapeutics Acquires Decuprate from Tactic Pharma 16
Venture Financing 17
Moderna Therapeutics Raises USD450 Million in Venture Financing 17
Wilson Therapeutics Raises US$40 Million In Series B Financing 19
Private Equity 21
TRC Capital To Acquire 0.77% Stake In Alexion Pharma For US$136 Million 21
Partnerships 22
Alexion Pharma and Complement Pharma Enter into Co-Development Partnership 22
Alexion Pharmaceuticals Enters into Partnership with Mount Sinai Genomics (Sema4) 23
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 24
X-Chem Enters into Discovery Agreement with Alexion Pharma 25
Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 26
Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 27
Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 28
Licensing Agreements 29
Alexion Pharma Enters into Licensing Agreement with Dicerna Pharma 29
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31
Xencor Enters into Licensing Agreement with Alexion Pharma 32
Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 34
Equity Offering 35
Wilson Therapeutics Raises USD29 Million in Private Placement of Shares 35
Wilson Therapeutics Raises USD48 Million in IPO 37
Synageva BioPharma Prices Public Offering of Shares for USD283 Million 39
Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 41
Synageva BioPharma Completes Public Offering Of Shares For US$211.5 Million 42
Synageva BioPharma Completes Public Offering Of Shares For US$179 Million 44
Synageva BioPharma Completes Public Offering Of Common Stock For US$118 Million 46
Synageva BioPharma Completes Public Offering Of Common Stock For US$115 Million 47
Synageva BioPharma Completes Public Offering Of Common Stock For US$90 Million 49
Asset Transactions 51
BridgeBio Pharma Acquires ALXN1101 from Alexion Pharma 51
Acquisition 52
Alexion Pharma Acquires Syntimmune 52
Alexion Acquires Wilson Therapeutics for USD852 Million 53
Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 55
Wilson Therapeutics Acquires TTM Europe Development from Medical Need Europe for USD6.2 Million 57
Alexion Pharma Completes Acquisition Of Enobia Pharma 58
Alexion Pharmaceuticals Inc – Key Competitors 60
Alexion Pharmaceuticals Inc – Key Employees 61
Alexion Pharmaceuticals Inc – Locations And Subsidiaries 62
Head Office 62
Other Locations & Subsidiaries 62
Recent Developments 65
Strategy And Business Planning 65
Sep 12, 2017: Alexion Announces Restructuring to Advance Corporate Strategy 65
Financial Announcements 67
Oct 24, 2018: Alexion reports third quarter 2018 results 67
Jul 26, 2018: Alexion Reports Second Quarter 2018 Results 69
Apr 26, 2018: Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study 71
Feb 08, 2018: Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018 73
Jul 27, 2017: Alexion Reports Second Quarter 2017 Results 75
Apr 27, 2017: Alexion Reports First Quarter 2017 Results 76
Feb 16, 2017: Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017 77
Corporate Communications 79
Feb 05, 2018: Alexion Pharmaceuticals Names Judith A. Reinsdorf As Board Director 79
Jan 22, 2018: Alexion Pharmaceuticals Names Deborah Dunsire As Board Director 80
Nov 08, 2017: Alexion Appoints Francois Nader, M.D. to its Board of Directors 81
Sep 14, 2017: Alexion Adds Paul A. Friedman, M.D. to Its Board of Director 82
Jun 13, 2017: Alexion Names Paul Clancy Chief Financial Officer 83
Jun 01, 2017: Alexion Announces Additions To Executive Leadership Team 84
May 23, 2017: Alexion Announces Executive Leadership Changes 86
Mar 27, 2017: Alexion Appoints Ludwig Hantson, Ph.D., As Chief Executive Officer 88
Mar 24, 2017: Alexion submits application to Japan’s MHLW to extend Soliris indication to treat gMG 89
Mar 02, 2017: Leonard Bell, M.D., Alexion’s Founder, Announces Plans to Retire as Chairman and Board Member 90
Product News 92
12/11/2017: Results Of Phase 1b/2 Dose Regimen Optimization Studies For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented At American Society Of Hematology (ASH) Meeting 92
11/01/2017: New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting 94
01/04/2017: Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016 95
Product Approvals 96
Aug 20, 2018: FDA accepts Priority Review of ALXN1210 as a treatment for patients with paroxysmal nocturnal hemoglobinuria in the US 96
Jun 28, 2018: Alexion Submits Application For Approval Of ALXN1210 as a Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) In The European Union (EU) 98
Jun 19, 2018: Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the U.S. 99
Dec 14, 2017: WTX101 Granted Fast Track Designation by the U.S. FDA for the Treatment of Wilson Disease 101
Jun 09, 2017: Wilson Therapeutics Receives US Orphan Drug Designation for WTX101 for the Treatment of ALS 102
Mar 08, 2017: FDA Accepts sBLA Filing of Soliris (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis 103
Jan 06, 2017: FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria 104
Clinical Trials 105
Jun 14, 2018: Alexion Announces Selection Of Positive Phase 3 Clinical Data For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) For Late-Breaking Oral Presentation At Annual Conference Of The European Hematology Association (EHA) 105
Jun 01, 2018: Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology 106
Apr 12, 2018: Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting 108
Mar 28, 2018: Preliminary Long-Term Data For WTX101 In Wilson Disease Accepted As A Late-Breaker Presentation At EASL Annual Meeting 110
Mar 15, 2018: Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 112
Feb 16, 2018: First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease 114
Oct 23, 2017: Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease 115
Oct 20, 2017: Promising Preliminary Long-term Data For WTX101 In Wilson Disease Highlighted at The Liver Meeting 117
Oct 06, 2017: Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology 119
Oct 01, 2017: Promising Preliminary Long-term Data from WTX101 Phase 2 Extension Study to be Presented at AASLD Annual Meeting 120
Jun 08, 2017: Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting 122
Apr 25, 2017: Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting 123
Apr 24, 2017: Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting 125
Apr 05, 2017: Final Phase 2 Results For WTX-101 Accepted As A Late-Breaker Presentation At EASL Annual Meeting 127
Mar 22, 2017: Alexion Submits Application In Japan For Soliris As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis 128
Jan 09, 2017: Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG) 129
Other Significant Developments 130
Jul 27, 2017: Moderna Provides Update on mRNA Rare Disease R&D Strategy 130
Jan 04, 2017: Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016 131
Appendix 133
Methodology 133
About GlobalData 133
Contact Us 133
Disclaimer 133

List of Tables
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Alexion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Wilson Therapeutics Acquires Decuprate from Tactic Pharma 16
Moderna Therapeutics Raises USD450 Million in Venture Financing 17
Wilson Therapeutics Raises US$40 Million In Series B Financing 19
TRC Capital To Acquire 0.77% Stake In Alexion Pharma For US$136 Million 21
Alexion Pharma and Complement Pharma Enter into Co-Development Partnership 22
Alexion Pharmaceuticals Enters into Partnership with Mount Sinai Genomics (Sema4) 23
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 24
X-Chem Enters into Discovery Agreement with Alexion Pharma 25
Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 26
Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 27
Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 28
Alexion Pharma Enters into Licensing Agreement with Dicerna Pharma 29
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31
Xencor Enters into Licensing Agreement with Alexion Pharma 32
Wilson Therapeutics Enters into Licensing Agreement with University of Michigan 34
Wilson Therapeutics Raises USD29 Million in Private Placement of Shares 35
Wilson Therapeutics Raises USD48 Million in IPO 37
Synageva BioPharma Prices Public Offering of Shares for USD283 Million 39
Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 41
Synageva BioPharma Completes Public Offering Of Shares For US$211.5 Million 42
Synageva BioPharma Completes Public Offering Of Shares For US$179 Million 44
Synageva BioPharma Completes Public Offering Of Common Stock For US$118 Million 46
Synageva BioPharma Completes Public Offering Of Common Stock For US$115 Million 47
Synageva BioPharma Completes Public Offering Of Common Stock For US$90 Million 49
BridgeBio Pharma Acquires ALXN1101 from Alexion Pharma 51
Alexion Pharma Acquires Syntimmune 52
Alexion Acquires Wilson Therapeutics for USD852 Million 53
Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 55
Wilson Therapeutics Acquires TTM Europe Development from Medical Need Europe for USD6.2 Million 57
Alexion Pharma Completes Acquisition Of Enobia Pharma 58
Alexion Pharmaceuticals Inc, Key Competitors 60
Alexion Pharmaceuticals Inc, Key Employees 61
Alexion Pharmaceuticals Inc, Subsidiaries 62

List of Figures
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[Alexion Pharmaceuticals Inc (ALXN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • The Leukemia & Lymphoma Society Inc-製薬・医療分野：企業M&A・提携分析
    Summary The Leukemia & Lymphoma Society Inc (LLS) is a health organization that offers funding research, finding cures and access to treatments for blood cancer patients. The organization’s services include patient support, health education, policy advocacy, funds raising and medical research fundin …
  • PolyPid Ltd (POLY)：医療機器：M&Aディール及び事業提携情報
    Summary PolyPid Ltd (PolyPid) is a pharmaceutical company that develops manufactures and commercializes therapies for the treatment of various medical conditions including infection, pain, inflammation and cancer. The company’s pipeline product candidates include D-Plex100, an antibiotic drug reserv …
  • Silence Therapeutics Plc (SLN)-製薬・医療分野：企業M&A・提携分析
    Summary Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a research and development company that develops and delivers RNA interference therapeutics for the treatment of serious diseases. The company's pipeline products include Atu027 and Atu111. Its Atu027 is developed for …
  • Northwest Territories Power Corp：企業の戦略的SWOT分析
    Northwest Territories Power Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Holding Slovenske elektrarne d.o.o.：企業の戦略的SWOT分析
    Holding Slovenske elektrarne d.o.o. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Recordati S.p.A.：企業のM&A・事業提携・投資動向
    Recordati S.p.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Recordati S.p.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Kamada Ltd (KMDA)：企業の財務・戦略的SWOT分析
    Kamada Ltd (KMDA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Genentech, Inc.：企業のM&A・事業提携・投資動向
    Genentech, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Genentech, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Indiabulls Real Estate Ltd：企業の戦略・SWOT・財務情報
    Indiabulls Real Estate Ltd - Strategy, SWOT and Corporate Finance Report Summary Indiabulls Real Estate Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Ethan Allen Interiors Inc. (ETH)：企業の財務・戦略的SWOT分析
    Ethan Allen Interiors Inc. (ETH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Mobile Tornado Group Plc (MBT)：企業の財務・戦略的SWOT分析
    Summary Mobile Tornado Group Plc (Mobile Tornado) is a technology company that offers communication services. The company offers solutions such as instant messaging solutions, voice communication, one-to-one and one-to-many; and instant alert that enables workforce to raise alerts in a range of situ …
  • WESCO International, Inc.：企業の戦略・SWOT・財務分析
    WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report Summary WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Bioceros BV-製薬・医療分野：企業M&A・提携分析
    Summary Bioceros BV (Bioceros) is a biopharmaceutical company which provides services related to preclinical development of monoclonal antibodies. The company offers GMP-ready protein producing cell lines. The company provides services which include monoclonal antibody generation, cell line and proc …
  • N V Nederlandse Gasunie：企業の戦略・SWOT・財務分析
    N V Nederlandse Gasunie - Strategy, SWOT and Corporate Finance Report Summary N V Nederlandse Gasunie - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • The Dun & Bradstreet Corporation：企業の戦略・SWOT・財務分析
    The Dun & Bradstreet Corporation - Strategy, SWOT and Corporate Finance Report Summary The Dun & Bradstreet Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Great Southern Bancorp Inc：企業の戦略・SWOT・財務分析
    Great Southern Bancorp Inc - Strategy, SWOT and Corporate Finance Report Summary Great Southern Bancorp Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Recepta Biopharma SA：製薬・医療：M&Aディール及び事業提携情報
    Summary Recepta Biopharma SA (Recepta) is a biotechnology company that offers research and development of drugs used in the treatment of cancer. The company offers antibodies and peptide products. It offers antibodies such as monoclonal antibody hu3s193 - anti-ley, monoclonal antibody 58-1066 - anti …
  • China National Petroleum Corp：石油・ガス：M&Aディール及び事業提携情報
    Summary China National Petroleum Corp (CNPC) is an integrated energy company. Its businesses cover oil and gas exploration and development, refining and chemicals, marketing and trading, pipeline transmission and stockpiling, technical services, engineering construction, equipment manufacturing, fin …
  • Itochu Techno-Solutions Corp (4739)：企業の財務・戦略的SWOT分析
    Itochu Techno-Solutions Corp (4739) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • PT Dian Swastatika Sentosa Tbk (DSSA)：企業の財務・戦略的SWOT分析
    PT Dian Swastatika Sentosa Tbk (DSSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆